The global chronic pain treatment market, valued at USD 78.0 billion in 2024, is projected to reach USD 83.4 billion in 2025 and USD 155.2 billion by 2035, representing a CAGR of 6.4% during the forecast period. Additionally, there are various pain management devices that have been reported to significantly reduce or eliminate the need for pharmacological interventions. Such devices are increasingly being used to treat a variety of clinical conditions that are characterized by chronic pain and o...

Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer’s disease) and is characterized by symptoms such as shaking, rigidity, difficulty in walking / movement, and several other cognitive and behavioral problems.

The respiratory disorders market is estimated to be worth $5 billion in 2018 and is expected to grow at compounded annual growth rate (CAGR) of 14.7% during the forecast period. According to the Forum of International Respiratory Societies, around 4 million individuals die each year due to chronic respiratory diseases. According to the data provided by the WHO, more than 3 million people die annually from COPD; this represents a total of 6% of the global annual deaths. Around 90% of these death...

TThe global Back of The Eye Disorders Drugs and Technologies Market is expected to be worth $22.9 billion by 2030. According to the World Health Organization, close to 250 million individuals, including 36 million blind people, presently suffer from some form of vision impairment. Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050. In fact, chronic eye diseases are considered to be o...

The cancer stem cell therapies market, valued at USD 2.8 billion in 2024, is projected to grow to USD 3.1 billion in 2025 and USD 8.0 billion by 2035, representing a CAGR of 10.0% during the forecast period. Over time, the development of CSCs has been shown to be associated with several signaling pathways, which regulate the survival and proliferation of these cells. Presently, a number of initiatives are underway to explore specific targets that can be used to selectively eliminate cancer stem...

The global non-antibody protein scaffolds drugs / diagnostics market is expected to be worth $6.2 billion by 2030, representing a CAGR of of 42% during the forecast period. Although the concept of non-antibody protein scaffolds was conceived more than a decade ago, this field has gained popularity in recent years. The first product candidate was launched in 1986; since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious dise...

The global antibody humanization market, valued at USD 5.7 billion in 2024, is projected to reach USD 6.2 billion in 2025 and USD 14.9 billion by 2035, representing a CAGR of 9.1% during the forecast period. The growing industry has faced / continues to face several challenges. One of the biggest hurdles to the growth of antibody-based products has been the lack of technical know-how across different stages of drug discovery. This situation is particularly true for the more traditional pharmaceu...

The global oncology drug discovery services market to grow at an annualized growth rate of 6.2% during the forecast period. The process of drug discovery is extremely demanding, both in terms of capital expenses and time. Specifically, the oncology market, with an estimated global prevalence of 32 million, imposes a heavy burden on the healthcare system. Over the years, outsourcing has emerged as a popular trend in the pharmaceutical and biotechnology industry, and has demonstrated the potential...

The global cancer metabolism therapeutics market, valued at USD 5.5 billion in 2024, is projected to reach USD 7.0 billion in 2025 and USD 53.6 billion by 2035, representing a CAGR of 22.5% during the forecast period. Cancer metabolism is based on the principle that cancer cells, as compared to normal cells, have different metabolic activities in order to support their enhanced energy and anabolic requirements. The pioneering discovery by Otto Warburg in the middle of the 20th century led to the...

The global BCMA targeted therapies market, valued at USD 9.2 billion in 2024, is projected to reach USD 11.8 billion in 2025 and USD 85.9 billion by 2035, representing a CAGR of 21.9% during the forecast period. B-cell maturation antigen (BCMA), an important biomarker of the B-cells, has emerged as a promising therapeutic target for the treatment of multiple myeloma and other hematological malignancies. The antigen is universally expressed on the surface of multiple myeloma cells. The research f...

Lupus is a serious, potentially fatal, autoimmune disease that attacks healthy tissue. It is worth metioning that Benlysta

The rheumatoid arthritis market, valued at USD 27.8 billion in 2024, is projected to reach USD 28.8 billion in 2025 and USD 40.1 billion by 2035, representing a CAGR of 3.4% during the forecast period. Several biopharmaceutical companies have been active in this area since last few years while others have recently stepped in. Apart from focusing on already established mechanisms of action, these companies are trying to offer novel and innovative treatment options. A number of collaborations and...

The global antibacterial drug resistance market, valued at USD 9.1 billion in 2024, is projected to reach USD 9.8 billion in 2025 and USD 18.8 billion by 2035, representing a CAGR of 6.7% during the forecast period. Several companies have made an attempt to develop new generation antibiotics that can combat widespread antibiotic drug resistance. These antibiotics are either the improved derivatives of existing antibiotics or combination products of antibiotics and β-lactamase inhibitors. In add...

The global ubiquitin enzymes market, valued at USD 3.0 billion in 2024, is projected to reach USD 3.3 billion in 2025 and USD 8.5 billion by 2035, representing a CAGR of 9.8% during the forecast period. The ubiquitin proteasome system (UPS) is one of the key protein degradation pathway involved in the control of protein homeostasis and turnover that mediates the regulation of several cellular processes. The UPS consists of two separate consecutive steps, ubiquitination and proteasomal degradatio...

The PDE inhibitors market, valued at USD 6.3 billion in 2024, is projected to reach USD 6.7 billion in 2025 and USD 12.7 billion by 2035, representing a CAGR of 6.6% during the forecast period. The success of the marketed PDE drugs has prompted several industry players to undertake initiatives in this area. The fragmented nature of the market is expected to increase the pace of innovation; as more molecules advance to late stage development and eventually get commercialized, we expect the new en...

The global dendritic cell cancer vaccines market is expected to reach $3.2 billion by 2030, growing at an annualized rate of over 20.7%. It is worth noting that in 2016, an estimated 1.7 million new cancer cases were reported in the US alone. Furthermore, as projected by the WHO, the annual incidence of cancer worldwide is expected to rise to 24 million by 2035. As a result, many pharmaceutical companies are working on identifying ways to improve treatment methods, as well as develop new cancer...

The global HDAC inhibitors market is estimated to grow from USD 1.2 billion in 2024 to reach USD 1.3 billion in 2025 and USD 2.8 billion by 2035, representing a higher CAGR of 7.8% during the forecast period. Currently, HDACs are widely being studied as a promising therapeutic target. HDAC inhibitors can be classified into four main categories based on the structural characteristics of the Zn2+ binding domain. These include hydroxamic acids, cyclic peptides, short-chain fatty acids and benzamide...

The non-insulin therapies market, valued at USD 32.8 billion in 2024, is projected to grow to USD 35.1 billion in 2025 and USD 65.2 billion by 2035, representing a CAGR of 6.4% during the forecast period. Several companies, including both big pharmaceutical players and small to mid-sized companies, are active in this area. Companies engaged in developing anti-diabetic drug classes have actively entered into collaborations with other stakeholders to either acquire / develop / commercialize candid...

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 inhibitor) was the first immune checkpoint inhibitor that was made commercially available in 2011 for treatment of patients suffering from unresectable or metastatic melanoma; it has enjoyed considerable success so far with annual sales of over USD 1 billion. Further, the market, with an opportunistic development pipeline, caters to the participation of various market players (big an...

After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. Notably, a high therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy. With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time...